Pancreatic Cancer :: Threshold pancreatic cancer drug glufosfamide fails in trial

Threshold Pharmaceuticals, Inc. (Nasdaq: THLD), announced that a Phase 3 trial of glufosfamide did not show a statistically significant improvement in overall survival compared to best supportive care (BSC) in patients with metastatic pancreatic cancer who had relapsed after gemcitabine chemotherapy.

While the overall survival in patients in the glufosfamide arm was 18% higher compared to those who received best supportive care alone, the result was not statistically significant.

“First and foremost, we thank all the patients and investigators who participated in this trial. It remains a challenge to identify new clinically significant treatments for this devastating disease, with still no approved treatment options in the second-line setting,” said Barry Selick, Ph.D., Threshold’s chief executive officer. “While there was a trend toward efficacy with glufosfamide, unfortunately the trial did not meet its efficacy endpoint. Based upon the activity seen in this, and previous studies, we remain committed to our ongoing trials with glufosfamide. Furthermore, we will continue to develop 2-deoxyglucose as well as our pre-clinical candidate HAP-302.”


Leave a Comment